Why It Matters
Elanco US Inc.’s $140,000 quarterly investment in Mercury Public Affairs LLC reflects urgent pressure to navigate a legislative landscape where policy decisions directly threaten and create market opportunities for animal health companies. Congress is actively reshaping regulations around methane emissions from livestock, foreign animal disease prevention, and feed additive approval processes—all central to Elanco’s business model.
Most critically, Elanco is pushing the Innovative FEED Act, which would create a streamlined regulatory pathway for products like its methane-reducing Bovaer additive. Without favorable legislative outcomes, competitors like Zoetis and Boehringer Ingelberg—equally invested in shaping these policies—may gain competitive advantages.
By the Numbers
Elanco US Inc. has invested approximately $894,000 across 20 lobbying disclosures since 2022. The company’s fourth quarter 2025 engagement with Mercury marks a significant strategic shift—a $140,000 quarterly payment that substantially exceeds typical spending patterns.
Historically, Elanco retained AnZu Strategies LLC for $494,000 across 13 disclosures through October 2025, and Apollo Government Relations LLC for $30,000 in 2025. The Mercury engagement represents expansion—adding firepower rather than consolidating representation.
Mercury’s diverse client portfolio includes Hyundai Motor America, Alibaba Group Holding Ltd., and foreign governments like Qatar, suggesting access to top congressional and executive branch decision-makers.
The Agenda
Elanco is lobbying on several core issues tied to its animal health business. Key priorities include the Innovative FEED Act, establishing a streamlined regulatory pathway for feed ingredients that reduce livestock emissions—directly benefiting Elanco’s Bovaer product.
Additional focus areas include foreign animal disease prevention through H.R. 3915, which would authorize $233 million annually for disease prevention programs. Elanco also engages on veterinary workforce development backed by the Senate Veterinary Medicine Caucus, and companion animal healthcare expansion including the PAW Act.
Broader Context
Congressional activity on animal health has intensified amid ongoing avian influenza concerns and methane regulation momentum. The 2025 Farm Bill expired September 30, creating legislative gridlock that makes targeted advocacy through specialized firms critical.
The Senate Veterinary Medicine Caucus is advancing workforce solutions while intensifying competition from Zoetis ($160,000 third quarter 2025 lobbying) and Boehringer Ingelheim creates pressure for elevated advocacy investment.
Between The Lines
Multiple congressional committees have prioritized foreign animal disease prevention amid H5 avian influenza outbreaks. Representative Kim Schrier introduced the Innovative FEED Act, establishing efficient regulatory pathways for gut-acting feed ingredients. The bipartisan Senate Veterinary Medicine Caucus focuses on veterinary shortages while the PAW Act (H.R. 1842) would allow HSA funds for veterinary expenses.
Competitive Landscape
Zoetis spent $160,000 on Q3 2025 lobbying targeting identical priorities including Farm Bill provisions and veterinary workforce development. Boehringer Ingelheim maintains consistent advocacy on disease preparedness programs. The Animal Health Institute lobbies on USDA appropriations and drug approvals while the American Veterinary Medical Association invested $215,000 in Q1 2025 on workforce development.
Elanco’s elevated Mercury investment reflects competitive necessity in a crowded legislative landscape where differentiated strategies become competitive advantages.
The Bottom Line
Elanco significantly escalated its federal lobbying by hiring Mercury for $140,000 in the last quarter of 2025. The move responds to converging policy pressures: avian flu outbreaks, methane regulations, fragmented Farm Bill processes, and aggressive competitor advocacy. Mercury’s Fortune 500 and international experience provides higher-level congressional access than previous agricultural specialists, positioning Elanco to navigate extended legislative uncertainty during a critical policy window.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article